Antisense Drug Against BCL-2 Effective in Animal Cancer Models

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targeted against the BCL-2 gene has proved effective against drug-resistant cancers in certain animal models of follicular lymphoma and colon cancer, the company said.

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targetedagainst the BCL-2 gene has proved effective against drug-resistantcancers in certain animal models of follicular lymphoma and coloncancer, the company said.

The BCL-2 gene is overexpressed in many tumors, preventing normalapoptosis and inducing drug resistance. A phase I/II trial indrug-resistant follicular lymphoma is scheduled to begin at TheRoyal Marsden Hospital, London, by mid-year.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Related Content